1,132 research outputs found
Electronic nicotine delivery systems: Emerging science foundation for policy
No full text[No abstract available]Agency for Toxic Substances and Disease Registry (ATSDR), 1997, TOX PROF PROP GLYC; *AM LEG FDN, E CIG PRES ARE E CIG; [Anonymous], WHO FRAM CONV TOB CO; BULLEN C, 2010, TOB CONTROL, V19, P8; Carter LP, 2009, CANCER EPIDEM BIOMAR, V18, P3241, DOI 10.1158-1055-9965.EPI-09-0948; CONNOLLY GN, 1986, NEW ENGL J MED, V314, P1020, DOI 10.1056-NEJM198604173141605; EISSENBERG T, 2010, TOB CONTROL, V19, P8; Henningfield JE, 2009, PHARMACOL THERAPEUT, V123, P1, DOI 10.1016-j.pharmthera.2009.03.011; Lunell E, 2000, EUR J CLIN PHARMACOL, V55, P737, DOI 10.1007-s002280050007; Schuster CR, 2009, DRUG ALCOHOL DEPEN, V105, pS4, DOI 10.1016-j.drugalcdep.2009.08.005; Schuster CR, 2003, DRUG ALCOHOL DEPEN, V70, pS1, DOI 10.1016-S0376-8716(03)00095-4; United State Food and Drug Administration, EL CIG; *US FDA, 2010, GUID IN PRESS; *US FDA, 2010, GUID COMPL REG INF; Wayne GF, 2008, NICOTINE TOB RES, V10, P613, DOI 10.1080-14622200801978698; WHO, 2009, WHO TECHNICAL REPORT, P3; *WHO, 2007, WHO TECHNICAL REPORT, P25; Wollscheid KA, 2009, AM J HEALTH-SYST PH, V66, P1740, DOI 10.2146-ajhp090127; TOTALLY WICKED ELIQU; WHO TOBACCO LAB NETW47484
Inferior Oblique Muscle Injury After Peribulbar Anesthesia Presenting as Ipsilateral Superior Oblique Palsy: A Clinicopathologic Report
No full text[No abstract available]Capo H, 1996, OPHTHALMOLOGY, V103, P918; Capo H, 1996, OPHTHALMOLOGY, V103, P721; CARLSON BM, 1992, OPHTHALMOLOGY, V99, P582; HUNTER DG, 1995, OPHTHALMOLOGY, V102, P501; Spierer A, 1999, J CATARACT REFR SURG, V25, P144, DOI 10.1016-S0886-3350(99)80025-X63
Testicular fibroma
No full text[No abstract available]Du SY, 2012, HUM PATHOL, V43, P144, DOI 10.1016-j.humpath.2011.04.017; GRECO MA, 1984, HUM PATHOL, V15, P238, DOI 10.1016-S0046-8177(84)80186-0; HONORE LH, 1975, J UROLOGY, V114, P631; Tobias-machado M, 2000, Urology, V56, P670, DOI 10.1016-S0090-4295(00)00736-61
ASPL-TFE3 translocation in vulvovaginal alveolar soft part sarcoma
No full textAlveolar soft part sarcoma of the vulvovaginal region is limited to only 8 reported vaginal cases and 1 vulvar case in the English literature. The histogenesis of the tumor remains intriguing with postulates favoring a myogenic versus nonmyogenic origin. A reciprocal translocation for ASPL-TFE3 gene fusion, frequently detected in ∼90percent of cases, combined with TFE3 protein immunoexpression are highly sensitive and specific methods for diagnostic confirmation. The current report describes a unique case of vulvovaginal alveolar soft part sarcoma showing the classic morphologic features with documentation of TFE3 protein expression and the ASPL-TFE3 gene rearrangement. Furthermore, a brief review of the literature of vulvar and vaginal alveolar soft part sarcoma cases with the various treatment modalities is outlined. © 2014 International Society of Gynecological Pathologists.Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097-PAS.0b013e3181f17ac0; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097-00000478-200306000-00005; CARINELLI SG, 1990, TUMORI, V76, P77; CHANG HC, 1994, J REPROD MED, V39, P121; CHAPMAN GW, 1984, GYNECOL ONCOL, V18, P125, DOI 10.1016-0090-8258(84)90016-7; CHRISTOPHERSON WM, 1952, CANCER, V5, P100, DOI 10.1002-1097-0142(195201)5:1100::AID-CNCR28200501123.0.CO;2-K; EVANS HL, 1985, CANCER, V55, P912, DOI 10.1002-1097-0142(19850215)55:4912::AID-CNCR28205504343.0.CO;2-G; Flannery T, 2010, INT J RADIAT ONCOL, V76, P513, DOI 10.1016-j.ijrobp.2009.02.007; Gomez JA, 1999, ARCH PATHOL LAB MED, V123, P503; He HY, 2011, INT J GYNECOL PATHOL, V30, P425, DOI 10.1097-PGP.0b013e318214dd4f; Hoshino M, 2009, CANCER GENET CYTOGEN, V190, P75, DOI 10.1016-j.cancergencyto.2008.11.014; KASAI K, 1980, GYNECOL ONCOL, V9, P227, DOI 10.1016-0090-8258(80)90031-1; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038-sj.onc.1204074; LIEBERMA.PH, 1966, J AMER MED ASSOC, V198, P1047, DOI 10.1001-jama.198.10.1047; Mitton Bryan, 2012, Sarcoma, P428789, DOI 10.1155-2012-428789; MUKAI M, 1983, AM J SURG PATHOL, V7, P679, DOI 10.1097-00000478-198310000-00008; NIELSEN GP, 1995, INT J GYNECOL PATHOL, V14, P283, DOI 10.1097-00004347-199510000-00001; OTOOLE RV, 1985, INT J GYNECOL PATHOL, V4, P258, DOI 10.1097-00004347-198509000-00011; Pang LJ, 2008, DIAGN MOL PATHOL, V17, P245, DOI 10.1097-PDM.0b013e31815d68d7; Rekhi B, 2012, PATHOLOGY, V44, P11, DOI 10.1097-PAT.0b013e32834d7ba4; Roma AA, 2005, INT J GYNECOL PATHOL, V24, P131, DOI 10.1097-01.PGP.0000148343.07759.E1; SHEN JT, 1982, GYNECOL ONCOL, V13, P120, DOI 10.1016-0090-8258(82)90017-8; Stockwin LH, 2009, BMC CANCER, V9, DOI 10.1186-1471-2407-9-22; Tobon H, 1976, Pa Med, V79, P55; Tsuji K, 2012, HUM PATHOL, V43, P356, DOI 10.1016-j.humpath.2011.05.004; ZALESKI S, 1986, ACTA CYTOL, V30, P6651
Lett Appl Microbiol
No full textThe most alarming aspect of the Sudanese toombak smokeless tobacco is that it contains high levels of highly toxic tobacco-specific nitrosamines (TSNAs). Understanding the microbiology of toombak is of relevance because TSNAs are an indirect result of microbial-mediated nitrate reductions. We conducted shotgun metagenomic sequencing on a toombak product for which relevant features are presented here. The microbiota was composed of over 99% Bacteria. The most abundant taxa included Actinobacteria, specifically the genera Enteractinococcus and Corynebacterium, while Firmicutes were represented by the family Bacillaceae and the genus Staphylococcus. Selected gene targets were nitrate reduction and transport, antimicrobial resistance, and other genetic transference mechanisms. Canonical nitrate reduction and transport genes (i.e. nar) were found for Enteractinococcus and Corynebacterium while various species of Staphylococcus exhibited a notable number of antimicrobial resistance and genetic transference genes. The nitrate reduction activity of the microbiota in toombak is suspected to be a contributing factor to its high levels of TSNAs. Additionally, the presence of antimicrobial resistance and transference genes could contribute to deleterious effects on oral and gastrointestinal health of the end user. Overall, the high toxicity and increased incidences of cancer and oral disease of toombak users warrants further investigation into the microbiology of toombak.CC999999/ImCDC/Intramural CDC HHSUnited States
Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population
No full textAims: A recently identified polymorphism in factor V gene (His1299Arg; also named HR2) has been reported to be a possible risk factor for the development of venous thromboembolism (VTE), with a high prevalence of 9.5-15.2percent in patients of different ethnic groups in different parts of the world. The aim of this study is to assess the prevalence of HR2 haplotype in Lebanon. Methods: We randomly selected 125 samples from unrelated donors logged into our HLA registry; these represent healthy Lebanese individuals originating from different provinces and religious communities of the country. Their DNA was extracted using the Pel-Freez extraction kit and stored at -80°C for later use. The CVD StripAssay was used for PCR and reverse hybridisation. It screens for several gene mutations including factor V H1299R. Results: A total of 125 controls were studied: 72 males and 53 females with a median age 42 years. Thirteen (10.4percent) had the HR2 haplotype; 11 (8.8percent) were heterozygous (R1-R2), and two (1.6percent) were homozygous (R2-R2), with an allelic frequency of 0.06. Conclusions: Our study is the first report from Lebanon that describes the prevalence of HR2 haplotype and the frequency of its alleles. We are reporting a high prevalence of the HR2 in our population (10.4percent). The hypothesis that A4070G polymorphism might contribute to the expression of a thrombotic phenotype deserves to be tested in our population through larger studies. © 2006 Royal College of Pathologists of Australasia.Akar N, 2000, HAEMOSTASIS, V30, P118; Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P193; Benson JM, 2001, THROMB HAEMOSTASIS, V86, P1188; Bernardi F, 1997, BLOOD, V90, P1552; BERTINA RM, 1995, THROMB HAEMOSTASIS, V74, P449; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038-369064a0; Castaman G, 1997, BRIT J HAEMATOL, V99, P257, DOI 10.1046-j.1365-2141.1997.3993213.x; Castoldi E, 2000, THROMB HAEMOSTASIS, V83, P362; DeStefano V, 1996, BLOOD, V87, P3531; de Visser MCH, 2000, THROMB HAEMOSTASIS, V83, P577; Doggen CJM, 2000, THROMB HAEMOSTASIS, V84, P815; Faioni EM, 1999, BLOOD, V94, P3062; Faioni EM, 2004, HAEMATOLOGICA, V89, P195; Herrmann FH, 2001, THROMB HAEMOSTASIS, V85, P1120; Jadaon MM, 2005, J THROMB HAEMOST, V3, P1467, DOI 10.1111-j.1538-7836.2005.01326.x; Kostka H, 2003, BLOOD COAGUL FIBRIN, V14, P49, DOI 10.1097-01.mbc.0000046197.72384.42; Lecumberri R, 2003, HAEMATOLOGICA, V88, P236; Luddington R, 2000, THROMB HAEMOSTASIS, V83, P204; Lunghi B, 1996, THROMB HAEMOSTASIS, V75, P45; Margaglione M, 2002, THROMB HAEMOSTASIS, V87, P32; Pecheniuk NM, 2001, BLOOD COAGUL FIBRIN, V12, P201, DOI 10.1097-00001721-200104000-00006; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; ROSING J, 1980, J BIOL CHEM, V255, P274; Yanqing Hu, 2003, Thrombosis and Haemostasis, V89, P44616141
Angiotensin-converting enzyme gene polymorphism and allele frequencies in the lebanese population: Prevalence and review of the literature
No full textWe studied the distribution of the D-D, I-D, and I-I genotypes of the angiotensin-converting enzyme (ACE) in a sample of healthy Lebanese individuals to assess their prevalence and compare them with other populations. ACE genotypes were determined using the Cardiovascular Disease (CVD) StripAssay, which is based on a Polymerase Chain Reaction-Reverse hybridization technique. DNA from 133 unrelated healthy donors from our HLA-bank was used. The prevalence of D-D, I-D, and I-I genotypes was found to be 39.1, 45.1, and 15.8percent respectively, with D and I allelic frequency of 61.7 and 38.3percent, respectively. The sampled Lebanese population showed ACE genotypic distributions similar to Caucasians; however, with tendency towards harboring high D allele frequency together with a low I allele frequency just like the Spanish population. This first report from Lebanon will serve as a baseline statistical data for future investigations of the prevalence of ACE genotypes in association with various clinical entities notably cardiovascular diseases. The medical literature was also reviewed in this context. © 2006 Springer Science+Business Media, Inc.Abbud ZA, 1998, AM J CARDIOL, V81, P244, DOI 10.1016-S0002-9149(97)00876-X; AgerholmLarsen B, 1997, CIRCULATION, V95, P2358; Agerholm-Larsen B, 2000, ARTERIOSCL THROM VAS, V20, P484; Al-Eisa A, 2001, SCAND J UROL NEPHROL, V35, P239; Alvarez R, 1998, CARDIOVASC RES, V40, P375, DOI 10.1016-S0008-6363(98)00179-5; Bautista LE, 2004, MED SCI MONITOR, V10, P473; Bouba I, 2003, EUR J OBSTET GYN R B, V110, P8, DOI 10.1016-S0301-2115(03)00046-0; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; Cicoira M, 2001, J AM COLL CARDIOL, V37, P1808, DOI 10.1016-S0735-1097(01)01237-2; Della Valle C J, 2001, BMC Musculoskelet Disord, V2, P1, DOI 10.1186-1471-2474-2-1; Dilley A, 1998, AM J EPIDEMIOL, V147, P30; DURU K, 1994, AM J HYPERTENS, V7, P759; DZAU VJ, 1991, HYPERTENSION, V18, P100; Fatini C, 2003, EUR J CLIN INVEST, V33, P642, DOI 10.1046-j.1365-2362.2003.01185.x; Ferrieres J, 1999, ATHEROSCLEROSIS, V142, P211, DOI 10.1016-S0021-9150(98)00204-4; Gonzalez Ordonez A. J., 2000, Blood Coagulation and Fibrinolysis, V11, P485, DOI 10.1097-00001721-200007000-00011; HIGASHIMORI K, 1993, BIOCHEM BIOPH RES CO, V191, P399, DOI 10.1006-bbrc.1993.1231; Hooper WC, 2002, AM J HEMATOL, V70, P1, DOI 10.1002-ajh.10078; Jackson A, 2000, BRIT J HAEMATOL, V111, P562, DOI 10.1046-j.1365-2141.2000.02408.x; Kim DK, 1997, ARTERIOSCL THROM VAS, V17, P3242; LEATHAM E, 1994, J HUM HYPERTENS, V8, P635; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056-NEJM199503163321103; Margaglione M, 1998, ARTERIOSCL THROM VAS, V18, P562; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016-0140-6736(93)92064-Z; MATTU RK, 1995, CIRCULATION, V91, P270; Murphey LJ, 2000, CIRCULATION, V102, P829; NAKAI K, 1994, CIRCULATION, V90, P2199; O'Donnell CJ, 1998, CIRCULATION, V97, P1766; Philipp CS, 1998, THROMB HAEMOSTASIS, V80, P869; Pinto YM, 1999, CARDIOVASC RES, V43, P23, DOI 10.1016-S0008-6363(99)00090-5; RAKUGI H, 1994, J CLIN INVEST, V93, P339, DOI 10.1172-JCI116965; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016-0140-6736(93)92061-W; Rice GI, 1999, CARDIOVASC RES, V41, P746, DOI 10.1016-S0008-6363(98)00246-6; RIDKER PM, 1993, CIRCULATION, V87, P1969; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172-JCI114844; Saeed M, 2005, HYPERTENS RES, V28, P345, DOI 10.1291-hypres.28.345; Samani NJ, 1996, CIRCULATION, V94, P708; SCHELLING P, 1991, J HYPERTENS, V9, P3; Schieffer B, 2000, ARTERIOSCL THROM VAS, V20, P281; SCHMIDT S, 1993, J HYPERTENS, V11, P345, DOI 10.1097-00004872-199304000-00003; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056-NEJM199406093302302; TIRET L, 1994, LANCET, V344, P910, DOI 10.1016-S0140-6736(94)92268-3; Uhm WS, 2002, LUPUS, V11, P227, DOI 10.1191-0961203302lu174oa; Vaughan DE, 1998, EUR HEART J, V19, P9; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172-JCI117809; von Depka M, 2003, THROMB HAEMOSTASIS, V89, P847; Wells PS, 2003, THROMB HAEMOSTASIS, V90, P829, DOI 10.1160-TH03-03-0170; Winkelmann BR, 1996, ANN INTERN MED, V125, P1921222
Chronic lymphocytic leukemia associated with myelodysplastic syndrome with ring sideroblasts
No full textDiagnosis of myelodysplastic syndrome-acute myeloid leukemia (MDS-AML) and chronic lymphocytic leukemia (CLL) in the same patient is extremely rare. We describe a 69-year-old CLL patient who developed MDS with ring sideroblasts 1 year after diagnosis of CLL and without any previous treatment. Diagnosis was based on flow cytometry, bone marrow aspirate morphology, and iron stain. Our findings indicate that the 2 disorders belong to 2 different hematopoietic clones in this patient. In cases of worsening anemia in CLL patients, it is recommended that an iron stain be performed on bone marrow aspirates to exclude a coexistent malignancy such as refractory anemia with ring sideroblasts. Copyright © 2010 by The Southern Medical Association.BASTION Y, 1991, LEUKEMIA, V5, P1006; BESSUDO A, 1995, LEUKEMIA LYMPHOMA, V18, P367, DOI 10.3109-10428199509059634; BRACEY AW, 1989, AM J HEMATOL, V30, P174, DOI 10.1002-ajh.2830300310; CATOVSKY D, 1971, LANCET, V1, P478; Cheson BD, 1999, J CLIN ONCOL, V17, P2454; COPPLESTONE JA, 1986, BRIT J HAEMATOL, V63, P149, DOI 10.1111-j.1365-2141.1986.tb07505.x; ESCRIBANOMORA L, 1977, SANGRE, V22, P639; FERRARA F, 1992, HAEMATOLOGICA, V77, P171; Florensa L, 1996, LEUKEMIA LYMPHOMA, V23, P609, DOI 10.3109-10428199609054871; FOUCAR K, 1992, NEOPLASTIC HEMATOPAT, P1181; Frewin RJ, 1997, CLIN LAB HAEMATOL, V19, P151, DOI 10.1046-j.1365-2257.1997.00229.x; Giles FJ, 1998, SEMIN ONCOL, V25, P117; Gottardi M, 2006, LEUKEMIA LYMPHOMA, V47, P885, DOI 10.1080-10428190500404761; GREENBERG BR, 1983, BRIT J HAEMATOL, V53, P125, DOI 10.1111-j.1365-2141.1983.tb01994.x; Hatoum HA, 2007, AM J HEMATOL, V82, P69, DOI 10.1002-ajh.20762; HULL MT, 1980, AM J CLIN PATHOL, V74, P473; KEATING MJ, 1993, BLOOD, V81, P2878; KORNBERG A, 1981, ACTA HAEMATOL-BASEL, V66, P127; Lai R, 1999, AM J CLIN PATHOL, V111, P373; Lam CCK, 2005, AM J HEMATOL, V79, P288, DOI 10.1002-ajh.20340; LAWLOR E, 1979, BRIT J HAEMATOL, V43, P369, DOI 10.1111-j.1365-2141.1979.tb03764.x; Lima M, 1996, CANCER GENET CYTOGEN, V87, P38, DOI 10.1016-0165-4608(95)00262-6; Lu CYM, 2006, AM J HEMATOL, V81, P963, DOI 10.1002-ajh.20716; Malani AK, 2007, ACTA ONCOL, V46, P247, DOI 10.1080-02841860600827139; MANOHARAN A, 1981, BRIT J HAEMATOL, V48, P111; MCCOY JP, 1995, ARCH PATHOL LAB MED, V119, P1038; McPherson RA, 2007, HENRYS CLIN DIAGNOSI; Miller MK, 2001, AM J DERMATOPATH, V23, P334, DOI 10.1097-00000372-200108000-00011; Mitterbauer G, 1997, ANN HEMATOL, V74, P193, DOI 10.1007-s002770050282; PAPAYANN.AG, 1974, BRIT J HAEMATOL, V28, P125, DOI 10.1111-j.1365-2141.1974.tb06646.x; ROBERTS PD, 1973, BRIT J HAEMATOL, V25, P203, DOI 10.1111-j.1365-2141.1973.tb01731.x; ROBERTSON LE, 1994, LEUKEMIA, V8, P2047; Rupniewska Zofia Monika, 1993, Acta Haematologica Polonica, V24, P57; SCHLAIFER D, 1994, NOUV REV FR HEMATOL, V36, P341; Shanafelt TD, 2004, MAYO CLIN PROC, V79, P388; SILBER R, 1990, WILLIAMS HEMATOLOGY, P245; Sorensen JM, 1997, J CLIN ONCOL, V15, P458; STERN N, 1981, CANCER, V47, P1849, DOI 10.1002-1097-0142(19810401)47:71849::AID-CNCR28204707223.0.CO;2-X; Sylvester LS, 1997, LEUKEMIA RES, V21, P619, DOI 10.1016-S0145-2126(97)00017-9; TAMBONEREYES M, 1992, LEUKEMIA RES, V16, P1055, DOI 10.1016-0145-2126(92)90086-M; TAMUL KR, 1994, CYTOMETRY, V18, P30, DOI 10.1002-cyto.990180107; WALLIS JP, 1986, ACTA HAEMATOL-BASEL, V75, P2290
Numerical simulation of free surface flows with steep gradients
No full textCivil Engineering and Geoscience
Finite element modelling of transport and non-hydrostatic flow in environmental fluid mechanics
No full textSectie VloeistofmechanicaCivil Engineering and Geoscience
- …
